Epstein–Barr virus (EBV) was the first tumour virus identified in humans. The virus is
primarily associated with lymphomas and epithelial cell cancers. These tumours express …

Epstein–Barr virus (EBV) contributes to about 1.5% of all cases of human cancer worldwide,
and viral genes are expressed in the malignant cells. EBV also very efficiently causes the …

Post-translational modification (PTM) of antigens provides an additional source of
specificities targeted by immune responses to tumors or pathogens, but identifying antigen …

It is more than 50 years since the Epstein–Barr virus (EBV), the first human tumour virus, was
discovered. EBV has subsequently been found to be associated with a diverse range of …

Hodgkin lymphoma (HL) is a B cell lymphoma characterized by few malignant cells and
numerous immune effector cells in the tumour microenvironment. The incidence of HL is …

Our understanding of familial predisposition to lymphoma (collectively defined as non-
Hodgkin lymphoma [NHL], Hodgkin lymphoma [HL], and chronic lymphocytic leukemia …

Hodgkin's lymphoma (HL) represents the most common subtype of malignant lymphoma in
young people in the Western world. Most patients can be cured with modern treatment …

Participants at the February 2011 meeting at the US National Institutes of Health on Epstein-
Barr virus (EBV) vaccine research recommend that future clinical trials have two goals …

Although a pathogenic role for the Epstein-Barr virus (EBV) is largely undisputed for tumors
that are consistently EBV genome positive (eg, nasopharyngeal carcinoma, endemic Burkitt …

Epstein-Barr virus (EBV) infection, history of infectious mononucleosis (IM) and HLA-A and
DRB1 have all been proposed as risk factors for multiple sclerosis (MS). Our aim was to …